COMP <GO>
EWTX vs ABBV // RSI-14 & 200D SMA MOMENTUM
Edgewise Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EWTX 2
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $38.91 (-3.90%) • MKT CAP: $4.23B
rsi-technicals
45.8
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 29.00% | -60.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | 3.47% | -6.88 | ABBV | /fcf-yield <GO> |
| Operating Margin | -16.20% | 24.60% | -40.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 8.60% | -9.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.8 | 65.1 | -19.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 113.1x | -88.10 | EWTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.23B | $513.86B | -$509.63B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | ABBV REV | EWTX GROSS % | ABBV GROSS % | EWTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$144.1M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$110.3M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$91.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
ABBV // BETA 1.15